Initial Validation of a Novel Protein Biomarker Panel for Active Pediatric Lupus Nephritis

Lupus nephritis (LN) is among the main determinants of poor prognosis in systemic lupus erythematosus (SLE). The objective of this study was to 1) isolate and identify proteins contained in the LN urinary protein signature (PS) of children with SLE; 2) assess the usefulness of the PS proteins for detecting activity of LN over time. Using surface-enhanced or matrix-assisted laser desorption/ionization time of flight mass spectrometry, the proteins contained in the LN urinary PS were identified. They were transferrin (Tf), ceruloplasmin (Cp), α1-acid-glycoprotein (AGP), lipocalin-type prostaglandin-D synthetase (L-PGDS), albumin, and albumin-related fragments. Serial plasma and urine samples were analyzed using immunonephelometry or ELISA in 98 children with SLE (78% African American) and 30 controls with juvenile idiopathic arthritis. All urinary PS proteins were significantly higher with active vs. inactive LN or in patients without LN (all p < 0.005), and their combined area under the receiver operating characteristic curve was 0.85. As early as 3 mo before a clinical diagnosis of worsening LN, significant increases of urinary Tf, AGP (both p < 0.0001), and L-PGDS (p < 0.01) occurred, indicating that these PS proteins are biomarkers of LN activity and may help anticipate the future course of LN.

[1]  H. Nagaraja,et al.  Biomarkers of lupus nephritis determined by serial urine proteomics. , 2008, Kidney international.

[2]  H. Nagaraja,et al.  Relationship between albuminuria and total proteinuria in systemic lupus erythematosus nephritis: diagnostic and therapeutic implications. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[3]  M. Klein-Gitelman,et al.  Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis , 2008, Pediatric Nephrology.

[4]  Chandra Mohan,et al.  Elevated Urinary VCAM-1, P-Selectin, Soluble TNF Receptor-1, and CXC Chemokine Ligand 16 in Multiple Murine Lupus Strains and Human Lupus Nephritis1 , 2007, The Journal of Immunology.

[5]  G. Ross,et al.  Identification of a urinary proteomic signature for lupus nephritis in children , 2007, Pediatric Nephrology.

[6]  John R Raymond,et al.  Urine biomarkers predict the cause of glomerular disease. , 2007, Journal of the American Society of Nephrology : JASN.

[7]  J. Ścieszka,et al.  Selected acute phase proteins and interleukin-6 in systemic lupus erythematosus patients treated with low doses of quinagolide , 2007, Autoimmunity.

[8]  H. Starklint,et al.  Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. , 2006, The Journal of rheumatology.

[9]  S. Umemura,et al.  Urinary excretions of lipocalin-type prostaglandin D2 synthase predict the development of proteinuria and renal injury in OLETF rats. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  J. Demuth,et al.  An effective skeletal muscle prefractionation method to remove abundant structural proteins for optimized two‐dimensional gel electrophoresis , 2005, Electrophoresis.

[11]  M. Gundogdu,et al.  Trace elements and some extracellular antioxidant proteins levels in serum of patients with systemic lupus erythematosus , 2005, Clinical Rheumatology.

[12]  M. Gomes,et al.  Acute-phase proteins and microalbuminuria among patients with type 2 diabetes. , 2004, Diabetes research and clinical practice.

[13]  D. Pappin,et al.  Suppression of alpha-cyano-4-hydroxycinnamic acid matrix clusters and reduction of chemical noise in MALDI-TOF mass spectrometry. , 2004, Analytical chemistry.

[14]  J. Hanley,et al.  Statistical analysis of correlated data using generalized estimating equations: an orientation. , 2003, American journal of epidemiology.

[15]  C. Bombardier,et al.  Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. , 2002, Arthritis and rheumatism.

[16]  Y. Toya,et al.  Lipocalin-Type Prostaglandin D Synthase in Essential Hypertension , 2002, Hypertension.

[17]  J. Gitlin,et al.  Ceruloplasmin metabolism and function. , 2002, Annual review of nutrition.

[18]  C. Bombardier,et al.  Sensitivity of the Systemic Lupus Erythematosus Disease Activity Index, British Isles Lupus Assessment Group Index, and Systemic Lupus Activity Measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus. , 1999, Arthritis and rheumatism.

[19]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[20]  J. Lacki,et al.  Cytokine concentration in serum of lupus erythematosus patients: the effect on acute phase response. , 1997, Journal of medicine.

[21]  A. Shevchenko,et al.  Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. , 1996, Analytical chemistry.

[22]  C. Meijer,et al.  Profiles of Cytokines (TNFα and IL-6) and Acute Phase Proteins (CRP and α1AG) related to the Disease Course in Patients with Systemic Lupus Erythematosus , 1993 .

[23]  D A Isenberg,et al.  The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. , 1993, The Quarterly journal of medicine.

[24]  C. Meijer,et al.  Profiles of cytokines (TNF alpha and IL-6) and acute phase proteins (CRP and alpha 1AG) related to the disease course in patients with systemic lupus erythematosus. , 1993, Lupus.

[25]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.